Physician profile
Michael S Strobbe
NPI 1437125002
$3,933.38
in general payments reported to CMS, 2019-2025
36 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $48.10 · 2021: $1,067 · 2022: $678 · 2023: $509 · 2024: $456 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $911.82 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $591.66 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $512.94 | 2021-2025 | |
| Glaxosmithkline, LLC. | $268.58 | 2022-2025 | Trelegy Ellipta |
| Abbvie INC. | $231.92 | 2021-2025 | Vraylar |
| Pfizer INC. | $194.15 | 2019-2025 | |
| Eisai INC. | $135.82 | 2021-2022 | |
| Horizon Therapeutics Plc | $126.42 | 2021-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.09 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $103.04 | 2019-2021 | |
| Amarin Pharma, INC. | $70.02 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $62.58 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $61.09 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $55.80 | 2019-2023 | Hetlioz |
| Phadia US INC. | $49.14 | 2021-2023 | Immunocap |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $47.02 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.33 | 2021-2022 | |
| Abbott Laboratories | $37.60 | 2021-2025 | Proclaim |
| Otsuka America Pharmaceutical, INC. | $36.14 | 2022-2023 | Rexulti |
| Smith+Nephew, INC. | $28.03 | 2021 | |
| Merck Sharp & Dohme LLC | $26.66 | 2019-2022 | |
| Gilead Sciences, INC. | $25.94 | 2022 | |
| Amgen INC. | $21.85 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.04 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.87 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $17.84 | 2025 | Inspire |
| Azurity Pharmaceuticals, INC. | $16.37 | 2024 | Horizant |
| Teva Pharmaceuticals USA, INC. | $15.84 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.76 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $15.53 | 2021 | |
| Lifescan, INC. | $14.11 | 2022 | |
| Lilly USA, LLC | $13.10 | 2024 | Mounjaro |
| Nestle Healthcare Nutrition INC. | $13.03 | 2021 | |
| Sun Pharmaceutical Industries INC. | $12.59 | 2020 | |
| Endo Pharmaceuticals INC. | $11.85 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Strobbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.